Ensuring HIV Data Availability, Transparency and Integrity in the MENA Region; Comment on “Improving the Quality and Quantity of HIV Data in the Middle East and North Africa: Key Challenges and Ways Forward”

Document Type : Commentary


1 U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA

2 Henry M. Jackson Foundation, Bethesda, MD, USA

3 Yale School of Public Health, Yale University, New Haven, CT, USA


In this commentary, we elaborate on the main points that Karamouzian and colleagues have made about HIV data scarcity in Middle Eastern and North African (MENA) countries. Without accessible and reliable data, no epidemic can be managed effectively or efficiently. Clearly, increased investments are needed to bolster capabilities to capture and interpret HIV surveillance data. We believe that this enhanced capacity can be achieved, in part, by leveraging and repurposing existing data platforms, technologies and patient cohorts. An immediate modest investment that capitalizes on available infrastructure can generate data on the HIV burden and spread that can be persuasive for MENA policy-makers to intensify efforts to track and contain the growing HIV epidemic in this region. A focus on key populations will yield the most valuable data, including among men who have sex with men (MSM), transgender women and men, persons who inject drugs (PWIDs), female partners of high risk men and female sex workers.


Main Subjects

  1. UNAIDS. Prevention Gap Report. http://www.unaids.org/en/resources/documents/2016/prevention-gap.  Published July 11, 2016.
  2. Karamouzian M, Madani N,  Doroudi F, Haghdoost AA. Improving the quality and quantity of HIV data in the Middle East and North Africa: key challenges and ways forward. Int J Health Policy Manag. 2017;6(2):65-69. doi:10.15171/ijhpm.2016.112
  3. Nazari SS, Noroozi M, Soori H, et al. The effect of on-site and outreach-based needle and syringe programs in people who inject drugs in Kermanshah, Iran. Int J Drug Policy. 2016;27:127-131. doi:10.1016/j.drugpo.2015.10.011
  4. Mumtaz GR, Riedner G, Abu-Raddad LJ. The emerging face of the HIV epidemic in the Middle East and North Africa. Curr Opin HIV AIDS.  204;9:183-191.  doi:10.1097/COH.0000000000000038
  5. Ruxin J, Binagwaho A, Wilson PA. Combating AIDS in the Developing World.  London: Earthscan; 2005.
  6. A World Survey of Sexual Orientation Laws. ILGA; 2016.
  7. Arab Strategic Framework for the Response to HIV and AIDS (2014-2020). http://www.menahra.org/en/menahra-resources/external-publications/427-arab-strategic-framework-for-the-response-to-hiv-and-aids-2020-2014.  Published March 2014.
  8. Amon JJ, Todrys KW. Fear of Foreigners: HIV-related restrictions on entry, stay, and residence. J Int AIDS Soc. 2008;11:8. doi:10.1186/1758-2652-11-8
  9. Chang F, Prytherch H, Nesbitt RC, Wilder-Smith A. HIV-related travel restrictions: trends and country characteristics. Glob Health Action. 2013;6:20472. doi:10.3402/gha.v6i0.20472
  10. World Health Organization. World Health Organization Global Influenza Programme. http://www.who.int/influenza/en/.  Published  2017.
  11. International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) website. https://isaric.tghn.org/.
  12. Abubakar A, Malik M, Pebody RG, et al. Burden of acute respiratory disease of epidemic and pandemic potential in the WHO Eastern Mediterranean Region: A literature review. East Mediterr Health J. 2016;22(7):513-526.
  13. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814-1820. doi:10.1056/NEJMoa1211721
  14. Shuaib F, Gunnala R, Musa EO, et al. Ebola virus disease outbreak - Nigeria, July-September 2014. MMWR Morb Mortal Wkly Rep 2014;63:867-872.
  15. Vaz RG, Mkanda P, Banda R, et al. The role of the polio program infrastructure in response to Ebola virus disease outbreak in Nigeria 2014. J Infect Dis. 2016;213 Suppl 3:S140-S1466.    doi:10.1093/infdis/jiv581
  16. Rolland M, Modjarrad K. Multiple co-circulating HIV-1 subtypes in the Middle East and North Africa. AIDS 2015;29:1417-1419. doi:10.1097/QAD.0000000000000764
  17. Fakhro KA, Staudt MR, Ramstetter MD, et al. The Qatar genome: a population-specific tool for precision medicine in the Middle East. Hum Genome Var. 2016;3:16016. doi:10.1038/hgv.2016.16
  18. GenBank. GenBank Overview. https://www.ncbi.nlm.nih.gov/genbank/.    
  19. Seale A. Nigeria, MSM, and the law: from evidence to strategy. Lancet HIV. 2015;2(7):e267-e268. doi:10.1016/S2352-3018(15)00107-1
  20. Schwartz, S. R. et al. The immediate eff ect of the Same-Sex Marriage Prohibition Act on stigma, discrimination, and engagement on HIV prevention and treatment services in men who have sex with men in Nigeria: analysis of prospective data from the TRUST cohort. Lancet HIV. 2015;2(7):e299-e306. doi:10.1016/S2352-3018(15)00078-8
  21. Lawrinson P, Ali R, Buavirat A, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008;103(9):1484-1492. doi:10.1111/j.1360-0443.2008.02249.x
  22. Naderi HR, Tagliamonte M, Tornesello ML, et al. Molecular and phylogenetic analysis of HIV-1 variants circulating among injecting drug users in Mashhad-Iran. Infect Agent Cancer. 2006;1:4.doi:10.1186/1750-9378-1-4
  23. Mumtaz GR, Weiss HA, Vickerman P, Larke N, Abu-Raddad LJ. Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa. AIDS. 2015;29(13):1701-1710. doi:10.1097/QAD.0000000000000761
  24. DeJong J, Battistin F. Women and HIV: the urgent need for more research and policy attention in the Middle East and North Africa region. J Int AIDS Soc. 2015;18:20084. doi:10.7448/IAS.18.1.20084
  25. Heijnen M, Mumtaz GR, Abu-Raddad LJ. Status of HIV and hepatitis C virus infections among prisoners in the Middle East and North Africa: review and synthesis. J Int AIDS Soc. 2016;19:20873. doi:10.7448/IAS.19.1.20873
  26. Himmich H, Madani N. The state of harm reduction in the Middle East and North Africa: a focus on Iran and Morocco. Int J Drug Policy 2016;31:184-189. doi:10.1016/j.drugpo.2016.02.013
  27. Vermund SH. The vital case for global health investments by the United States Government. Clin Infect Dis. 2017. doi:10.1093/cid/cix048
  • Receive Date: 12 February 2017
  • Revise Date: 22 May 2017
  • Accept Date: 24 April 2017
  • First Publish Date: 01 December 2017